Surgery Partners, Inc.
NASDAQ:SGRYMedical - Care Facilities
+$0.06 today
- Market cap
- $3.53B
- Beta
- 1.95
- P/E (TTM)
- -24.1
- EPS (TTM)
- -$0.59
Volume 3.24M
Average 1.36M
SGRY Depreciation & Amortization
Non-cash expense that spreads the cost of physical and intangible assets over their useful lives.
Surgery Partners, Inc.NASDAQ: SGRY
Depreciation & Amortization · Q3 FY2026 · quarter ended Sep 2026
Depreciation & amortization grows, but more slowly than its trailing trend
Q3 FY2026 depreciation & amortization of $39.6M rose 0.3% year over year, behind the +18.2% change in trailing-twelve-month depreciation & amortization. Sequentially, it rose 0.8% from the prior quarter. Over 3 fiscal years it compounded at +15.3% a year.
Context
- Depreciation & amortization amounted to 5.3% of revenue in FY2025, up 0.4 pp from a year earlier.
- Depreciation & amortization increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from +0.3% toward the trailing-twelve-month pace of +18.2%.
Sources:Income StatementText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the income statement
- Latest · FY2025
- 176M USD
- Year-over-year change
- +15.3%
- 4-year CAGR
- +15.5%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 176M | +15.3% |
| FY2024 | 2024-12-31 | 152.6M | +29.2% |
| FY2023 | 2023-12-31 | 118.1M | +2.9% |
| FY2022 | 2022-12-31 | 114.8M | +16.2% |
| FY2021 | 2021-12-31 | 98.8M | — |
Depreciation & Amortization vs competitors
How SGRY compares with its peers on the latest reported figures
- SGRY's LTM Sep 2026 depreciation & amortization of $177.3M is the 5th highest of the 7 companies compared; the peer median is $687.58M.
- Its year-over-year change of +18.2% is the 2nd highest of 7, against a peer median of +8.4%.
- Depreciation & amortization amounts to 5.3% of revenue for SGRY, versus a peer median of 3.5%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $3.67B | +7.4% | +5.9% | 4.7% | |
| LTM Jun 2026 | $893M | +9.4% | +0.9% | 4.1% | |
| LTM Mar 2026 | $734M | +85.4% | -1.7% | 3.4% | |
| LTM Jun 2026 | $641.16M | +7.5% | +2.1% | 3.5% | |
| LTM Sep 2026 | $177.3M | +18.2% | +15.3% | 5.3% | |
ARDTArdent Health Partners, LLC | LTM Mar 2026 | $162.49M | +10.4% | +4.1% | 2.5% |
| LTM Mar 2026 | $20.93M | +5.3% | +16.1% | 2.4% | |
| Peer median (excluding SGRY) | $687.58M | +8.4% | +3.1% | 3.5% | |
Competitors are the stored peer set for SGRY. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 2.23B | 2.54B | 2.74B | 3.11B | 3.31B |
| Cost of Revenue | 1.73B | 1.96B | 2.1B | 2.37B | 2.54B |
| Gross Profit | 491.4M | 574.9M | 647.5M | 745.6M | 765M |
| Gross Margin | 22.1% | 22.6% | 23.6% | 23.9% | 23.1% |
| Research & Development | 0 | 0 | 0 | 0 | 0 |
| Selling, General & Admin | 104M | 102.2M | 120.9M | 138.7M | 522.7M |
| Operating Expenses | 189.2M | 229.7M | 319.5M | 396.8M | 375.5M |
| Depreciation & Amortization | 98.8M | 114.8M | 118.1M | 152.6M | 176M |
| EBITDA | 401M | 460M | 446.1M | 501.4M | 565.5M |
| EBITDA Margin | 18.0% | 18.1% | 16.3% | 16.1% | 17.1% |
| Operating Income | 302.2M | 345.2M | 328M | 348.8M | 389.5M |
| Operating Margin | 13.6% | 13.6% | 12.0% | 11.2% | 11.8% |
| Interest Income | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 221M | 234.9M | 193M | 201.7M | 272.6M |
| Other Income / Expenses | (221M) | (234.9M) | (193M) | (201.7M) | (272.6M) |
| Income Before Tax | 81.2M | 110.3M | 135M | 147.1M | 116.9M |
| Pre-Tax Margin | 3.6% | 4.3% | 4.9% | 4.7% | 3.5% |
| Income Tax Expense | 10.5M | 23.3M | (300K) | 134.6M | 18M |
| Net Income | (70.9M) | (54.6M) | (11.9M) | (168.1M) | (77.9M) |
| Net Margin | -3.2% | -2.2% | -0.4% | -5.4% | -2.4% |
| EPS (Basic) | (1.12) | (0.59) | (0.09) | (1.33) | (0.61) |
| EPS (Diluted) | (1.12) | (0.59) | (0.09) | (1.33) | (0.61) |
| Weighted Avg Shares | 72.43M | 91.95M | 125.61M | 126.12M | 127.21M |
| Weighted Avg Shares (Diluted) | 72.43M | 91.95M | 125.61M | 126.12M | 127.21M |
Surgery Partners, Inc.
NASDAQ:SGRY
Intrinsic Alpha fair value
Locked
Current Price
$26.96
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.